1. Home
  2. INBS vs AKTX Comparison

INBS vs AKTX Comparison

Compare INBS & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

INBS

Intelligent Bio Solutions Inc.

HOLD

Current Price

$2.61

Market Cap

5.7M

Sector

Health Care

ML Signal

HOLD

Logo Akari Therapeutics plc ADS

AKTX

Akari Therapeutics plc ADS

HOLD

Current Price

$5.51

Market Cap

6.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INBS
AKTX
Founded
2016
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.7M
6.7M
IPO Year
2019
2014

Fundamental Metrics

Financial Performance
Metric
INBS
AKTX
Price
$2.61
$5.51
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$33.50
AVG Volume (30 Days)
75.3K
47.6K
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
68.65
N/A
EPS
N/A
N/A
Revenue
$1,980,484.00
N/A
Revenue This Year
$778.48
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.54
$0.12
52 Week High
$24.90
$6.46

Technical Indicators

Market Signals
Indicator
INBS
AKTX
Relative Strength Index (RSI) 35.94 70.06
Support Level $2.42 $0.27
Resistance Level $7.25 $5.50
Average True Range (ATR) 0.23 0.53
MACD 0.07 -0.00
Stochastic Oscillator 20.27 65.15

Price Performance

Historical Comparison
INBS
AKTX

About INBS Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company operates through new reportable segments: United Kingdom; Asia Pacific (APAC); Americas; and Rest of World, of which United Kingdom derives maximum revenue.

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.

Share on Social Networks: